Predictors of clinically significant quality of life impairment in Parkinson's disease.
Journal
NPJ Parkinson's disease
ISSN: 2373-8057
Titre abrégé: NPJ Parkinsons Dis
Pays: United States
ID NLM: 101675390
Informations de publication
Date de publication:
16 Dec 2021
16 Dec 2021
Historique:
received:
25
03
2021
accepted:
27
07
2021
entrez:
17
12
2021
pubmed:
18
12
2021
medline:
18
12
2021
Statut:
epublish
Résumé
Quality of life (QOL) plays an important role in independent living in Parkinson's disease (PD) patients, being crucial to know what factors impact QoL throughout the course of the disease. Here we identified predictors of QoL impairment in PD patients from a Spanish cohort. PD patients recruited from 35 centers of Spain from the COPPADIS cohort from January 2016, to November 2017, were followed up during 2 years. Health-related QoL (HRQoL) and global QoL (GQoL) were assessed with the 39-item Parkinson's disease Questionnaire (PDQ-39) and the EUROHIS-QOL 8-item index (EUROHIS-QOL8), respectively, at baseline (V0) and at 24 months ± 1 month (V2). Clinically significant QoL impairment was defined as presenting an increase (PDQ-39SI) or decrement (EUROHIS-QOL8) at V2 ≥ 10% of the score at baseline (V0). A comparison with a control group was conducted for GQoL. GQoL did not change significantly in PD patients (N = 507; p = 0.686) or in the control group (N = 119; p = 0.192). The mean PDQ-39SI was significantly increased in PD patients (62.7 ± 8.5 years old; 58.8% males; N = 500) by 21.6% (from 16.7 ± 13 to 20.3 ± 16.4; p < 0.0001) at V2. Ninety-three patients (18.6%) presented a clinically significant HRQoL impairment at V2. To be younger (OR = 0.896; 95% CI 0.829-0.968; p = 0.006), to be a female (OR = 4.181; 95% CI 1.422-12.290; p = 0.009), and to have a greater increase in BDI-II (Beck Depression Inventory-II) (OR = 1.139; 95% CI 1.053-1.231; p = 0.001) and NMSS (Non-Motor Symptoms Scale) (OR = 1.052; 95% CI 1.027-1.113; p < 0.0001) total scores from V0 to V2 were associated with clinically significant HRQoL impairment at the 2-year follow-up (Hosmer-Lemeshow test, p = 0.665; R
Identifiants
pubmed: 34916528
doi: 10.1038/s41531-021-00256-w
pii: 10.1038/s41531-021-00256-w
pmc: PMC8677846
doi:
Types de publication
Journal Article
Langues
eng
Pagination
118Investigateurs
Daniela A Adarmes
(DA)
Marta Almeria
(M)
Araceli Alonso Cánovas
(A)
F Alonso Frech
(F)
Ruben Alonso Redondo
(R)
Ignacio Álvarez
(I)
Ángel Aneiros Díaz
(Á)
Sandra Arnáiz
(S)
Sonia Arribas
(S)
Arancha Ascunce Vidondo
(A)
Noemí Bernardo Lambrich
(N)
Helana Bejr-Kasem
(H)
María A Botí
(MA)
María T Buongiorno
(MT)
Carolina Cabello González
(C)
A Cámara Lorenzo
(A)
Héctor Canfield Medina
(H)
Fátima Carrillo
(F)
Elena Casas
(E)
Ana Cortina Fernández
(A)
Anna Cots Foraster
(A)
Ane Crespo Cuevas
(A)
Mónica Díez-Fairen
(M)
Julio Dotor García-Soto
(J)
Elena Erro
(E)
Elena Estelrich Peyret
(E)
Noelia Fernández Guillán
(N)
Pedro Gámez
(P)
Mercedes Gallego
(M)
Cristina García Campos
(C)
Jose M García Moreno
(JM)
María P Gómez Garre
(MP)
Vívtor Gómez Mayordomo
(V)
Javier González Aloy
(J)
Beatriz González García
(B)
María J González Palmás
(MJ)
González Toledo
(G)
R Gabriel
(R)
Ana Golpe Díaz
(A)
Mireia Grau Solá
(M)
Gemma Guardia
(G)
Andrea Horta-Barba
(A)
Daniel Idoate Calderón
(D)
Jon Infante
(J)
Carmen Labandeira
(C)
Miguel A Labrador
(MA)
Francisco Lacruz
(F)
Melva Lage Castro
(M)
Sonia Lastres Gómez
(S)
Balbino López Seoane
(B)
Sara Lucas Del Pozo
(S)
Yolanda Macías
(Y)
Marina Mata
(M)
Gloria Martí Andres
(G)
María J Martí
(MJ)
Maria T Meitín
(MT)
Manuel Menéndez González
(M)
Carlota Méndez Del Barrio
(C)
Javier Miranda Santiago
(J)
Morales Casado
(M)
I María
(I)
Antonio Moreno Diéguez
(A)
Alba Novo Amado
(A)
Sabela Novo Ponte
(S)
Javier Pagonabarraga
(J)
Isabel Pareés
(I)
Berta Pascual-Sedano
(B)
Aída Pérez Fuertes
(A)
Rafael Pérez Noguera
(R)
Ana Planas-Ballvé
(A)
Marian A Prats
(MA)
Cristina Prieto Jurczynska
(C)
Mercedes Pueyo Morlans
(M)
Arnayu Puig Daví
(A)
Nuria Redondo Rafales
(N)
Luisa Rodríguez Méndez
(L)
Amparo B Rodríguez Pérez
(AB)
Florinda Roldán
(F)
Macarena Sánchez-Carpintero
(M)
Gemma Sánchez Díez
(G)
Antonio Sánchez Rodríguez
(A)
Pilar Santacruz
(P)
José C Segundo Rodríguez
(JC)
María Sierra Peña
(M)
Juan P Tartari
(JP)
Laura Vargas
(L)
Clara Villanueva
(C)
Bárbara Vives
(B)
María D Villar
(MD)
Informations de copyright
© 2021. The Author(s).
Références
Chaudhuri, K. R. et al. The nondeclaration of nonmotor symptoms of Parkinson’s disease to health care professionals: an international study using the nonmotor symptoms questionnaire. Mov. Disord. 25, 704–709 (2010).
pubmed: 20437539
doi: 10.1002/mds.22868
Hinnell, C. et al. Nonmotor versus motor symptoms: how much do they matter to health status in Parkinson’s disease? Mov. Disord. 27, 236–241 (2012).
pubmed: 21954027
doi: 10.1002/mds.23961
Schrag, A., Jahanshahi, M. & Quinn, N. What contributes to quality of life in patients with Parkinson’s disease? J. Neurol. Neurosurg. Psychiatry 69, 308–312 (2000).
pubmed: 10945804
pmcid: 1737100
doi: 10.1136/jnnp.69.3.308
Kuopio, A. M., Marttila, R. J., Helenius, H., Toivonen, M. & Rinne, U. K. The quality of life in Parkinson’s disease. Mov. Disord. 15, 216–223 (2000).
pubmed: 10752569
doi: 10.1002/1531-8257(200003)15:2<216::AID-MDS1003>3.0.CO;2-#
Muslimovic, D., Post, B., Speelman, J. D., Schmand, B. & de Haan, R. J. Determinants of disability and quality of life in mild to moderate Parkinson disease. Neurology 70, 2241–2247 (2008).
pubmed: 18519873
doi: 10.1212/01.wnl.0000313835.33830.80
Behari, M., Srivastava, A. K. & Pandey, R. M. Quality of life in patients with Parkinson’s disease. Parkinsonism Relat. Disord. 11, 221–226 (2005).
pubmed: 15878582
doi: 10.1016/j.parkreldis.2004.12.005
Karlsen, K. H., Larsen, J. P., Tandberg, E. & Maland, J. G. Quality of life measurements in patients with Parkinson’s disease: a communitybased study. Eur. J. Neurol. 5, 443–450 (1998).
pubmed: 10210872
doi: 10.1046/j.1468-1331.1998.550443.x
Rahman, S., Griffin, H. J., Quinn, N. P. & Jahanshahi, M. Quality of life in Parkinson’s disease: the relative importance of the symptoms. Mov. Disord. 23, 1428–1434 (2008).
pubmed: 18543333
doi: 10.1002/mds.21667
Slawek, J., Derejko, M. & Lass, P. Factors affecting the quality of life of patients with idiopathic Parkinson’s disease-a cross-sectional study in an outpatient clinic attendees. Parkinsonism Relat. Disord. 11, 465–468 (2005).
pubmed: 16154794
doi: 10.1016/j.parkreldis.2005.04.006
Chapuis, S., Ouchchane, L., Metz, O., Gerbaud, L. & Durif, F. Impact of the motor complications of Parkinson’s disease on the quality of life. Mov. Disord. 20, 224–230 (2005).
pubmed: 15384126
doi: 10.1002/mds.20279
Karlsen, K. H., Larsen, J. P., Tandberg, E. & Maeland, J. G. Influence of clinical and demographic variables on quality of life in patients with Parkinson’s disease. J. Neurol. Neurosurg. Psychiatry 66, 431–435 (1999).
pubmed: 10201412
pmcid: 1736304
doi: 10.1136/jnnp.66.4.431
Martinez-Martin, P. et al. The impact of non-motor symptoms on health-related quality of life of patients with Parkinson’s disease. Mov. Disord. 26, 399–406 (2011).
pubmed: 21264941
doi: 10.1002/mds.23462
Santos García, D. & de la Fuente-Fernández, R. Impact of non-motor symptoms on health-related and perceived quality of life in Parkinson’s disease. J. Neurol. Sci. 332, 136–140 (2013).
pubmed: 23890935
doi: 10.1016/j.jns.2013.07.005
Santos García, D. et al. Non-motor symptoms burden, mood, and gait problems are the most significant factors contributing to a poor quality of life in non-demented Parkinson’s disease patients: results from the COPPADIS Study Cohort. Parkinsonism Relat. Disord. 66, 151–157 (2019).
pubmed: 31409572
doi: 10.1016/j.parkreldis.2019.07.031
Martinez-Martin, P. What is quality of life and how do we measure it? Relevance to Parkinson’s disease and movement disorders. Mov. Disord. 32, 382–392 (2017).
pubmed: 27911002
doi: 10.1002/mds.26885
Martinez-Martin, P. & Kurtis, M. M. Health-related quality of life as an outcome variable in Parkinson’s disease. Ther. Adv. Neurol. Disord. 5, 105–117 (2012).
pubmed: 22435075
pmcid: 3302201
doi: 10.1177/1756285611431974
Soh, S. E., Morris, M. E. & McGinley, J. L. Determinants of health-related quality of life in Parkinson’s disease: a systematic review. Parkinsonism Relat. Disord. 17, 1–9 (2011).
pubmed: 20833572
doi: 10.1016/j.parkreldis.2010.08.012
Karlsen, K. H., Tandberg, E., Arsland, D. & Larsen, J. P. Health related quality of life in Parkinson’s disease: a prospective longitudinal study. J. Neurol. Neurosurg. Psychiatry 69, 584–589 (2000).
pubmed: 11032608
pmcid: 1763406
doi: 10.1136/jnnp.69.5.584
Prakash, K. M., Nadkarni, N. V., Lye, W. K., Yong, M. H. & Tan, E. K. The impact of non-motor symptoms on the quality of life of Parkinson’s disease patients: a longitudinal study. Eur. J. Neurol. 23, 854–860 (2016).
pubmed: 26806538
doi: 10.1111/ene.12950
Higginson, I. J. et al. Symptoms and quality of life in late stage Parkinson syndromes: a longitudinal community study of predictive factors. PLoS ONE 7, e46327 (2012).
pubmed: 23144781
pmcid: 3492372
doi: 10.1371/journal.pone.0046327
Visser, M., Verbaan, D., van Rooden, S., Marinus, J., van Hilten, J. & Stiggelbout, A. A longitudinal evaluation of health-related quality of life of patients with Parkinson’s disease. Value Health 12, 392–396 (2009).
pubmed: 18657099
doi: 10.1111/j.1524-4733.2008.00430.x
Reuther, M. et al. Assessing health-related quality of life in patients with Parkinson’s disease in a prospective longitudinal study. Parkinsonism Relat. Disord. 13, 108–114 (2007).
pubmed: 17055326
doi: 10.1016/j.parkreldis.2006.07.009
Abraham, D. S. et al. Sex differences in Parkinson’s disease presentation and progression. Parkinsonism Relat. Disord. 69, 48–54 (2019).
pubmed: 31677455
pmcid: 6982644
doi: 10.1016/j.parkreldis.2019.10.019
Klietz, M. et al. Impaired quality of life and need for palliative care in a German Cohort of advanced Parkinson’s disease patients. Front. Neurol. 9, 120 (2018).
pubmed: 29559949
pmcid: 5845640
doi: 10.3389/fneur.2018.00120
Fasano, A. et al. Characterizing advanced Parkinson’s disease: OBSERVE-PD observational study results of 2615 patients. BMC Neurol. 19, 50 (2019).
pubmed: 30940119
pmcid: 6444751
doi: 10.1186/s12883-019-1276-8
Valkovic, P., Harsany, J., Hanakova, M., Martinkova, J. & Benetin, J. Nonmotor symptoms in early- and advanced-stage Parkinson’s disease patients on dopaminergic therapy: how do they correlate with quality of life? ISRN Neurol. 2014, 587302 (2014).
pubmed: 24729891
pmcid: 3963114
doi: 10.1155/2014/587302
Velseboer, D. C. et al. Prognostic factors of motor impairment, disability, and quality of life in newly diagnosed PD. Neurology 80, 627–633 (2013).
pubmed: 23345637
doi: 10.1212/WNL.0b013e318281cc99
Post, B. et al. Progression and prognostic factors of motor impairment, disability and quality of life in newly diagnosed Parkinson’s disease. Mov Disord. 26, 449–456 (2011).
pubmed: 21312273
doi: 10.1002/mds.23467
Antonini, A. et al. The progression of non-motor symptoms in Parkinson’s disease and their contribution to motor disability and quality of life. J. Neurol. 259, 2621–2631 (2012).
pubmed: 22711157
doi: 10.1007/s00415-012-6557-8
Simuni, T. et al. Baseline prevalence and longitudinal evolution of non-motor symptoms in early Parkinson’s disease: the PPMI cohort. J. Neurol. Neurosurg. Psychiatry. 89, 78–88 (2018).
pubmed: 28986467
doi: 10.1136/jnnp-2017-316213
Horváth, K. et al. Changes in quality of life in Parkinson’s disease: how large must they be to be relevant? Neuroepidemiology 48, 1–8 (2017).
pubmed: 28161701
doi: 10.1159/000455863
Ou, R. et al. Progression of non-motor symptoms in Parkinson’s disease among different age populations: a two-year follow-up study. J. Neurol. Sci. 360, 72–77 (2016).
pubmed: 26723977
doi: 10.1016/j.jns.2015.11.047
Ringash, J., O’Sullivan, B., Bezjak, A. & Redelmeier, D. A. Interpreting clinically significant changes in patient-reported outcomes. Cancer 110, 196–202 (2007).
pubmed: 17546575
doi: 10.1002/cncr.22799
Peto, V., Jenkinson, C. & Fitzpatrick, R. Determining minimally important differences for the PDQ-39 Parkinson’s disease questionnaire. Age Ageing 30, 299–302 (2001).
pubmed: 11509307
doi: 10.1093/ageing/30.4.299
Brozek, J. L., Guyatt, G. H. & Schünemann, H. J. How a well-grounded minimal important difference can enhance transparency of labelling claims and improve interpretation of a patient reported outcome measure. Health Qual. Life Outcomes 27, 69 (2006).
doi: 10.1186/1477-7525-4-69
Barrett, B., Brown, D., Mundt, M. & Brown, R. Sufficiently important difference: expanding the framework of clinical significance. Med. Decis. Making 25, 250–261 (2005).
pubmed: 15951453
doi: 10.1177/0272989X05276863
Deng, X. et al. Four-year longitudinal study of motor and non-motor symptoms in LRRK2-related Parkinson’s disease. Front. Neurol. 10, 1379 (2020).
pubmed: 32010044
pmcid: 6978710
doi: 10.3389/fneur.2019.01379
van Wamelen, D. J. et al. International Parkinson and Movement Disorder Society Parkinson’s Disease Non-Motor Study Group. The Non-Motor Symptoms Scale in Parkinson’s disease: validation and use. Acta Neurol. Scand. 143, 3–12 (2021).
pubmed: 32813911
doi: 10.1111/ane.13336
Martinez-Martin, P. et al. Gender-related differences in the burden of non-motor symptoms in Parkinson’s disease. J. Neurol. 259, 1639–1647 (2012).
pubmed: 22237822
doi: 10.1007/s00415-011-6392-3
Guo, X. et al. Disease duration-related differences in non-motor symptoms: a study of 616 Chinese Parkinson’s disease patients. J. Neurol. Sci. 330, 32–37 (2013).
pubmed: 23601697
doi: 10.1016/j.jns.2013.03.022
Song, W. et al. The impact of non-motor symptoms on the health-related quality of life of Parkinson’s disease patients from Southwest China. Parkinsonism Relat. Disord. 20, 149–152 (2014).
pubmed: 24161377
doi: 10.1016/j.parkreldis.2013.10.005
Wu, Y. et al. Determinants of the quality of life in Parkinson’s disease: results of a cohort study from Southwest China. J. Neurol. Sci. 340, 144–149 (2014).
pubmed: 24679837
doi: 10.1016/j.jns.2014.03.014
Ray Chaudhuri, K. et al. Burden of non-motor symptoms in Parkinson’s disease patients predicts improvement in quality of life during treatment with levodopa-carbidopa intestinal gel. Eur. J. Neurol. 26, 581–e43 (2019).
pubmed: 30353942
doi: 10.1111/ene.13847
Erro, R. et al. The non-motor side of the honeymoon period of Parkinson’s disease and its relationship with quality of life: a 4-year longitudinal study. Eur. J. Neurol. 23, 1673–1679 (2016).
pubmed: 27435448
doi: 10.1111/ene.13106
Santos-García, D. et al. Sleep problems are related to a worse quality of life and a greater non-motor symptoms burden in Parkinson’s disease. Int. J. Geriatr. Psychiatry 34, 642–658 (2021).
Rafferty, M. R. et al. Regular exercise, quality of life, and mobility in Parkinson’s disease: a longitudinal analysis of National Parkinson Foundation quality improvement initiative data. J. Parkinsons. Dis. 7, 193–202 (2017).
pubmed: 27858719
pmcid: 5482526
doi: 10.3233/JPD-160912
Santos García, D. et al. Safinamide improves non-motor symptoms burden in Parkinson’s disease: an open-label prospective study. Brain Sci. 11, 316 (2021).
pubmed: 33801565
pmcid: 7999475
doi: 10.3390/brainsci11030316
Shulman, L. M. Gender differences in Parkinson’s disease. Gend. Med. 4, 8–18 (2007).
pubmed: 17584622
doi: 10.1016/S1550-8579(07)80003-9
Crispino, P. et al. Gender differences and quality of life in Parkinson’s disease. Int. J. Environ. Res. Public. Health 18, 198 (2020).
pmcid: 7795924
doi: 10.3390/ijerph18010198
Yoon, J. E. et al. Gender differences of nonmotor symptoms affecting quality of life in Parkinson disease. Neurodegener. Dis. 17, 276–280 (2017).
pubmed: 28848156
doi: 10.1159/000479111
Schrag, A., Hovris, A., Morley, A., Quinn, A. & Jahanshahi, M. Young- versus older-onset Parkinson’s disease: impact of disease and psychosocial consequences. Mov. Disord. 18, 1250–1256 (2003).
pubmed: 14639664
doi: 10.1002/mds.10527
Mehanna, R. & Jankovic, J. Young-onset Parkinson’s disease: Its unique features and their impact on quality of life. Parkinsonism Relat. Disord. 65, 39–48 (2019).
pubmed: 31176633
doi: 10.1016/j.parkreldis.2019.06.001
Shahgholi, L. et al. Hospitalization and rehospitalization in Parkinson disease patients: data from the National Parkinson Foundation Centers of Excellence. PLoS ONE 12, e0180425 (2017).
pubmed: 28683150
pmcid: 5500337
doi: 10.1371/journal.pone.0180425
Santos García, D. et al. Staging Parkinsonas disease combining motor and nonmotor symptoms correlates with disability and quality of life. Parkinsons Dis. 2021, 8871549 (2021).
pubmed: 34094501
pmcid: 8140853
Santos-García, D. et al. COPPADIS Study Group. COPPADIS-2015 (COhort of Patients with PArkinson’s DIsease in Spain, 2015), a global-clinical evaluations, serum biomarkers, genetic studies and neuroimaging-prospective, multicenter, non-interventional, long-term study on Parkinson’s disease progression. BMC Neurol. 16, 26 (2016).
pubmed: 26911448
pmcid: 4766717
doi: 10.1186/s12883-016-0548-9
Santos García, D. et al. COPPADIS Study Group. COPPADIS-2015 (COhort of Patients with PArkinson’s DIsease in Spain, 2015): an ongoing global Parkinson’s disease project about disease progression with more than 1000 subjects included. Results from the baseline evaluation. Eur. J. Neurol. 26, 1399–1407 (2019).
pubmed: 31179586
doi: 10.1111/ene.14008
Daniel, S. E. & Lees, A. J. Parkinson’s Disease Society Brain Bank, London: overview and research. J. Neural. Transm. Suppl. 39, 165–172 (1993).
pubmed: 8360656
Hoehn, M. M. & Yahr, M. D. Parkinsonism: onset, progression and mortality. Neurology 17, 427–442 (1967).
pubmed: 6067254
doi: 10.1212/WNL.17.5.427
Fanhn, S., Elton, R. L. & Members of the UPDRS Development Committee. in Recent Developments in Parkinson’s Disease (eds. Fahn, S., Marsden, C. D., Calne, D. B. & Goldstein M.) Vol. 2, 153–164 (Macmillan Health Care Information, Florham Park, NJ, 1987).
Giladi, N., Shabtai, H., Simon, E. S., Biran, S., Tal, J. & Korczyn, A. D. Construction of freezing of gait questionnaire for patients with Parkinsonism. Parkinsonism Relat. Disord. 6, 165–170 (2000).
pubmed: 10817956
doi: 10.1016/S1353-8020(99)00062-0
Chaudhuri, K. R. et al. The metric properties of a novel non-motor symptoms scale for Parkinson’s disease: Results from an international pilot study. Mov. Disord. 22, 1901–1911 (2007).
pubmed: 17674410
doi: 10.1002/mds.21596
Chaudhuri, K. R. et al. The Parkinson’s disease sleep scale: a new instrument for assessing sleep and nocturnal disability in Parkinson’s disease. J. Neurol. Neurosurg. Psychiatry 73, 629–635 (2002).
pubmed: 12438461
pmcid: 1757333
doi: 10.1136/jnnp.73.6.629
Burckhardt, C. S. & Jones, K. D. Adult measures of pain: The McGill Pain Questionnaire (MPQ), Rheumatoid Arthritis Pain Scale (RAPS), Short Form McGill Pain Questionnaire (SF-MPQ), Verbal Descriptive Scale (VDS), Visual Analog Scale (VAS), and West Haven-Yale Multidisciplinary Pain Inventory (WHYMPI). Arthritis. Rheum. 49, 96–104 (2003).
doi: 10.1002/art.11440
Tseng, B. Y., Gajewski, B. J. & Kluding, P. M. Reliability, responsiveness, and validity of the visual analog fatigue scale to measure exertion fatigue in people with chronic stroke: a preliminary study. Stroke. Res. Treat. 2010, 412964 (2010).
pubmed: 20700421
pmcid: 2911654
Folstein, M. F., Folstein, S. E. & McHugh, P. R. Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 12, 189–198 (1975).
pubmed: 1202204
doi: 10.1016/0022-3956(75)90026-6
Pagonabarraga, J., Kulisevsky, J., Llebaria, G., García-Sánchez, C., Pascual-Sedano, B. & Gironell, A. Parkinson’s disease-cognitive rating scale: a new cognitive scale specific for Parkinson’s disease. Mov. Disord. 23, 998–1005 (2008).
pubmed: 18381647
doi: 10.1002/mds.22007
Beck, A. T., Steer, R. A. & Brown, G. K. Beck Depression Inventory 2nd ed (The Psychological Corporation, San Antonio, 1996).
Cummings, J. L., Mega, M., Gray, K., Rosenberg-Thompson, S., Carusi, D. A. & Gornbein, J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 44, 2308–2314 (1994).
pubmed: 7991117
doi: 10.1212/WNL.44.12.2308
Weintraub, D. et al. Validation of the questionnaire for impulsive-compulsive disorders in Parkinson’s disease. Mov. Disord. 24, 1461–1467 (2009).
pubmed: 19452562
pmcid: 2848971
doi: 10.1002/mds.22571
Schwab, R. S. & England, A. C. In Third Symposium on Parkinson’s Disease 152–157 (E. And S. Livingstone, Edinburgh, 1969).
Jenkinson, C., Fitzpatrick, R., Peto, V., Greenhall, R. & Hyman, N. The Parkinson’s Disease Questionnaire (PDQ-39): development and validation of a Parkinson’s disease summary index score. Age Ageing 26, 353–357 (1997).
pubmed: 9351479
doi: 10.1093/ageing/26.5.353
Da Rocha, N. S., Power, M. J., Bushnell, D. M. & Fleck, M. P. The EUROHIS-QOL 8-item index: comparative psychometric properties to its parent WHOQOL-BREF. Value Health 15, 449–457 (2012).
pubmed: 22583455
doi: 10.1016/j.jval.2011.11.035
Santos-García, D. et al. COPPADIS Study Group. Non-motor symptom burden is strongly correlated to motor complications in patients with Parkinson’s disease. Eur. J. Neurol. 27, 1210–1223 (2020).
pubmed: 32181979
doi: 10.1111/ene.14221
Cohen, J. & Cohen, P. Applied Multiple Regression/Correlation Analysis for the Behavioral Sciences 2nd ed (Lawrence Erlbaum, Hillsdale, New Jersey, 1983).
Schade, S., Mollenhauer, B. & Trenkwalder, C. Levodopa equivalent dose conversion factors: an updated proposal including opicapone and safinamide. Mov. Disord. Clin. Pract. 2020, 343–345 (2020).
doi: 10.1002/mdc3.12921